2021
DOI: 10.1007/s40272-021-00469-9
|View full text |Cite
|
Sign up to set email alerts
|

Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance

Abstract: Neuroblastoma is the most common extracranial solid tumour in children, accounting for 15% of all paediatric cancer deaths. High-risk neuroblastoma is a particularly challenging-to-treat form of disease that requires multimodality treatment, consisting of chemotherapy, surgery, high-dose chemotherapy with autologous haematopoietic stem cell rescue, radiotherapy and differentiation therapy. However, despite intense multimodal treatment regimens, the prognosis for this patient population remains poor. In recent … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
37
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 25 publications
(38 citation statements)
references
References 18 publications
1
37
0
Order By: Relevance
“…Before the introduction of immunotherapy, long-term remission could be achieved in about 40% of HR patients with multimodal treatment including induction chemotherapy, surgery, myeloablative chemotherapy with autologous stem cell rescue, radiation and maintenance therapy with isotretinoin (1-3). Anti-disialoganglioside 2 (anti-GD2)-based immunotherapy has altered the perspective for patients with high-risk NB (4).…”
Section: Introductionmentioning
confidence: 99%
“…Before the introduction of immunotherapy, long-term remission could be achieved in about 40% of HR patients with multimodal treatment including induction chemotherapy, surgery, myeloablative chemotherapy with autologous stem cell rescue, radiation and maintenance therapy with isotretinoin (1-3). Anti-disialoganglioside 2 (anti-GD2)-based immunotherapy has altered the perspective for patients with high-risk NB (4).…”
Section: Introductionmentioning
confidence: 99%
“…Treatment with 3F8 and naxitamab proved safe, feasible, and effective in HR‐NB infants. Acute toxicity was similar with the two mAbs and was indistinguishable from that observed with these 4‐7 and other anti‐G D2 mAbs 12,14,15,32 in older patients. The short infusions and manageable toxicity allowed outpatient treatment.…”
Section: Discussionmentioning
confidence: 52%
“…In line with data from the HR-NBL1 SIOPEN study, the tolerability profile of dinutuximab beta generally improved with subsequent cycles [ 8 ], and all AEs were manageable with supportive therapy. Pain, which was one of the most common AEs in patients receiving dinutuximab beta in clinical trials [ 8 , 21 ], was well managed with analgesics as recommended [ 14 ]. Only two patients reported moderate pain in the current case series, one of whom also received IL-2, which has been shown to be associated with a higher incidence of pain when combined with dinutuximab beta [ 8 , 21 ].…”
Section: Discussionmentioning
confidence: 99%
“…Pain, which was one of the most common AEs in patients receiving dinutuximab beta in clinical trials [ 8 , 21 ], was well managed with analgesics as recommended [ 14 ]. Only two patients reported moderate pain in the current case series, one of whom also received IL-2, which has been shown to be associated with a higher incidence of pain when combined with dinutuximab beta [ 8 , 21 ]. The feasibility, tolerability and effectiveness of dinutuximab beta administration in real-world clinical practice was also demonstrated in a recent single-center experience in Slovakia [ 22 , 23 ].…”
Section: Discussionmentioning
confidence: 99%